| Document |
Document Title |
|
WO/2024/049348A1 |
The present invention provides a modified immune cell, which comprises a T cell receptor (TCR) capable of specifically targeting hepatitis B surface antigen (HBsAg) and a chimeric conversion receptor. The chimeric conversion receptor use...
|
|
WO/2024/050524A1 |
Provided herein are compositions for increasing Apolipoprotein L1 (ApoL1) in target cells. The ApoL1 can be a recombinant protein or an endogenous protein optionally in a ApoL1-containing complex. Antibodies and other binding molecules t...
|
|
WO/2024/047178A1 |
Disclosed is a method and compounds useful for performing said method for simultaneous synthesis of a plurality of oligonucleotide molecules, and more specifically for orthogonal synthesis of at least two different oligonucleotide molecu...
|
|
WO/2024/050501A2 |
The present disclosure, relates, in general to analogs of proline-rich polypeptide 1 (PRP-1) designated tyrosine peptides (TYR peptide) that are useful to treat cancer, such as sarcomas, carcinomas and leukemias or liquid cancers.
|
|
WO/2024/048418A1 |
Provided is a diagnostic antibody that is capable of detecting PD-L1 in tumors for novel therapies for feline tumors targeting PD-1/PD-L1. The anti-PD-L1 antibody contains: (a) an L-chain having CDR1 that has the amino acid sequence ES...
|
|
WO/2024/049232A1 |
The present invention relates to a fusion polypeptide comprising a polypeptide containing a transmembrane domain (TMD) having the C-terminus and the N-terminus to which a polypeptide of general formula I is bound, and the fusion polypept...
|
|
WO/2024/049307A1 |
The present disclosure provides microbial strains, including fungal and yeast strains, which are useful for protein expression. Also provided are expression constructs, expression systems, growth media, and methodology for achieving expr...
|
|
WO/2024/049161A1 |
The present invention relates to a novel antibody or an antigen-binding fragment thereof, which specifically binds to PD-L1, a chimeric antigen receptor comprising an antigen-binding variable fragment of the antibody, immune cells expres...
|
|
WO/2024/047155A1 |
The present invention relates to novel host cells capable of degrading starch and/or utilizing starch as a carbon source wherein said host cell comprising one or more of the following sequences: (a) a polypeptide having at least 97% iden...
|
|
WO/2024/050285A2 |
Compositions and methods are provided for preventing or treating obesity and/or overweight, and managing body weight. Compositions comprise partial agonists of the leptin receptor (lepr), including variant leptin polypeptides, which part...
|
|
WO/2024/050478A1 |
Provided herein are chimeric receptors comprising an amyloid-reactive peptide, as well as cells comprising the chimeric receptors. Also provided herein are methods of treating amyloid-based diseases by administering a cell comprising a c...
|
|
WO/2024/050503A1 |
The present disclosure is generally related to the fields of microbial host cells, molecular biology, protein engineering, fermentation, protein production, and the like. Certain aspects of the disclosure are related to novel promoter an...
|
|
WO/2024/050440A2 |
PSMA targeted metal chelate nanodrugs, methods of making these nanodrugs and methods of using them for radiodiagnosis and radiotherapy are provided.
|
|
WO/2024/050001A1 |
Described is a polypeptide including the intracellular domain of CX3CL1 (CX3CL1- ICD), including an amino acid sequence that is at least 90% identical to SEQ ID NO: 1 and pharmaceutical compositions including the above-described polypept...
|
|
WO/2024/050064A1 |
The invention described herein provides an engineered hybrid capsid for adeno- associated virus (AAV), which capsid is a chimeric fusion between two different clinically validated AAV capsids with different AAV serotypes for enhanced nuc...
|
|
WO/2024/047091A2 |
The present invention relates to compositions comprising modified virus-like particles (VLPs) of Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising chimeric CMV polypeptides which comprises a stretch of con...
|
|
WO/2024/049355A1 |
The present invention relates to live attenuated flaviviruses and immunogenic composition of flaviviruses. The disclosure specifically relates to live attenuated Dengue- 1, Dengue-2, Dengue-3, and Dengue-4 viruses comprising 11 14T mutat...
|
|
WO/2024/049946A1 |
An immunogen includes an immunogenic carrier and an antigenic apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC) peptide linked to the immunogenic carrier. In one or more embodiments, the...
|
|
WO/2024/047218A1 |
Described herein are compositions and methods to produce masked antibodies useful in a variety of therapeutic indications.
|
|
WO/2024/047130A1 |
Relaxin-2 for use as a broad-spectrum substitute of glucocorticoids, mineralocorticoids, corticosteroids and their analogues for treating tissue and endothelial injuries without incurring inducing gluconeogenesis, Cushing's syndrome and ...
|
|
WO/2024/047110A1 |
The present invention relates to a new method to obtain more effective CAR-T cells. Here, the inventors worked on the function of FOXO1 in T lymphocyte physiology for many years. They recently described, using a FOXO1 pharmacological inh...
|
|
WO/2024/050451A2 |
Described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 19. Also described herein is a composition comprising nucleic acid sequ...
|
|
WO/2024/046234A1 |
The present invention relates to an antibody that specifically binds to complement C5, and a fusion protein thereof. The present invention also relates to a polynucleotide, an expression vector, and a host cell that encode the antibody o...
|
|
WO/2024/046312A1 |
The present invention belongs to the technical field of biology, and particularly relates to a recombinant protein and the use thereof. The recombinant protein contains: an SH protein (SH) of the respiratory syncytial virus and a G prote...
|
|
WO/2024/050452A2 |
It has been discovered that immunogens of conserved proteins from Gram-negative bacteria (GNB) co-administered with IL1α provoke a strong T-cell response to the bacteria from which the immunogens were derived. The compositions further p...
|
|
WO/2024/050555A1 |
Disclosed herein include methods and compositions for use in generating synthetic embryos. In some embodiments, the method comprises culturing stem cells that over-express at least one Cadherin.
|
|
WO/2024/050267A1 |
The present disclosure is directed to oligonucleotide dendrons comprising an oligonucleotide stem linked to one or more oligonucleotide branches. The disclosure also provides methods of using the oligonucleotide dendrons.
|
|
WO/2024/050450A1 |
The present disclosure relates to a novel, engineered enveloped vector that can be used for gene delivery. The engineered enveloped vector comprises an engineered envelope comprising: (a) a viral envelope protein and optionally, (b) a no...
|
|
WO/2024/049990A1 |
The present disclosure relates generally to vaccines against orthopoxviruses, and methods for making and using such vaccines. In particular, in some embodiments, the present disclosure relates to nanoparticle-derived vaccines, and compos...
|
|
WO/2024/050058A2 |
The present disclosure provides UL141 variants with one or more mutations, pharmaceutical compositions, diagnostic compositions, and kits containing the variants, nucleic acids and expression vectors encoding the variants, cells comprisi...
|
|
WO/2024/046280A1 |
Provided are a polyethylene glycol-modified IL-21 derivative and the use thereof. By analyzing the structure of IL-21, under the condition that the overall structure of IL-21 is not affected, specific sites in IL-21 are mutated into cyst...
|
|
WO/2024/050512A2 |
Disclosed herein are compositions and methods for treating, and for the preventative treatment of Lyme disease. Also disclosed herein are compositions and methods for detecting and diagnosing infection by a Borrelia sp.
|
|
WO/2024/045430A1 |
The present invention relates to the technical field of biological functions of proteins, and specifically relates to a polypeptide, a fused polymer protein and the use thereof. The polypeptide is selected from: (1) a polypeptide that ha...
|
|
WO/2024/048792A1 |
The present disclosure provides a composition for treating viral infections. In one mode, the present disclosure provides a composition that is for treating viral infections in subjects, and that includes a nucleic acid construct having,...
|
|
WO/2024/046429A1 |
The present invention belongs to the field of biotechnology, and provides a mutant insecticidal protein Vip3 and the use thereof. The mutant insecticidal protein Vip3 is obtained by performing point mutation on original sequences of vari...
|
|
WO/2024/049864A1 |
Described herein are, among other things, compositions and methods for antibody screening.
|
|
WO/2024/011071A9 |
Provided herein are methods and compositions for conferring cellular resistance to viral infection.
|
|
WO/2024/048570A1 |
The present invention addresses the problem of providing a vaccine composition for nasal administration that is usable for preventing and treating hepatitis B, and a nasal administration system of the vaccine. Provided is a hepatitis B...
|
|
WO/2024/050289A1 |
The present invention relates to a dosage form suitable for oral administration comprising a therapeutic peptide or protein in a sealed capsule having a co-polymer coating.
|
|
WO/2024/046404A1 |
A recombinant botulinum toxin and a preparation method therefor. By designing and optimizing the heavy chain and light chain sequences of the recombinant botulinum toxin, adding and cleaving protein tags will not introduce amino acid res...
|
|
WO/2024/046322A1 |
The present disclosure provides agonistic IL-15 complexes that have therapeutic use, and methods for making such proteins. The present disclosure additionally provides methods of treating disease in a subject in need thereof by administe...
|
|
WO/2024/045153A1 |
Provided is a method for improving the expression level of a recombinant human albumin, which comprises expressing the recombinant human albumin, and weakening, destroying or removing the function of at least one endogenous gene encoding...
|
|
WO/2024/044863A1 |
The invention relates to a method for generating a porous injectable scaffold, which comprises: providing a two-phase liquid composition at a temperature below 25°C, with Newtonian behaviour, wherein the composition comprises a dispersa...
|
|
WO/2024/046994A1 |
Disclosed are methylglyoxal resistant genetically engineered microbial cells for the fermentative production of an oligosaccharide of interest, and methods for fermentative production of an oligosaccharide of interest using the methylgly...
|
|
WO/2024/050488A2 |
The invention is directed to modified HIV-1 envelopes, compositions comprising these modified envelopes, nucleic acids encoding these modified envelopes, compositions comprising these nucleic acids, and methods of using these modified HI...
|
|
WO/2024/048688A1 |
The present disclosure provides an opsin that has a light cycle characteristic. Specifically, the present disclosure provides a protein including an amino acid sequence of an opsin, wherein the amino acid sequence of the opsin includes a...
|
|
WO/2024/050007A1 |
Aspects of the disclosure relate to Botulinum toxin X (BoNT X) protein variants. The variants provided herein have been evolved to cleave GTP cyclohydrolase 1 (GCH1). Some of the variants provided herein were evolved from a procaspase- 1...
|
|
WO/2024/047002A1 |
The present invention relates to provision of bacteria for promoting plant health under abiotic stress conditions, such as high salinity. In particular, the present invention relates to provision of bio-stimulant derivative Bacillus vele...
|
|
WO/2024/048978A1 |
The present invention relates to a TMEM165-CLOCK antibody epitope, an antibody specifically binding thereto or an antigen-binding fragment of the antibody, and a composition comprising the antibody or the antigen-binding fragment thereof...
|
|
WO/2024/047151A1 |
The technology described herein relates to new CRISPR/Cas systems and components thereof, vectors, proteins, fusion proteins, ribonucleoprotein complexes and methods of using the new system and components. The new system can be used in C...
|
